Literature DB >> 8740046

The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands.

G Griebel1, D J Sanger, G Perrault.   

Abstract

The behavioral effects of a wide range of BZ (omega) receptor ligands, including non-selective full (alprazolam, clorazepate, chlordiazepoxide and diazepam) and partial (bretazenil, imidazenil and Ro 19-8022) agonists, and selective BZ-1 (omega 1) (abecarnil, CL 218,872, CL 284,846 and zolpidem) receptor ligands, were compared in the rat elevated plus-maze test. Behaviors recorded comprised the traditional indices of anxiety as well as a number of ethologically derived measures. In addition, the specificity of drug effects was evaluated by measuring spontaneous locomotor activity in activity cages in separate groups of animals. Results showed that all compounds tested not only increased the proportion of time spent and proportion of entries into the open arms of the maze (considered as traditional indices of anxiety) but also affected head-dippings and attempts at entry into open arms, which can be considered as indices of risk assessment responses. However, the magnitude of these effects was generally smaller with the BZ-1 (omega 1) selective agents. Moreover, additional differences were apparent on the total number of arm entries measure, which was significantly increased by most full and all partial agonists, but was unaffected by the selective BZ-1 (omega 1) compounds. If it is assumed that total arm entries are contaminated by anxiety, the latter finding indicates a weaker anxiety-reducing potential of selective BZ-1 (omega 1) ligands. Importantly, the increase in total arm entries induced by the non-selective agents was not associated with a similar effect on locomotion as revealed in the actimeter. Finally, anxiolysis produced by the BZ-1 (omega 1) ligands was invariably observed at doses which reduced locomotor activity, suggesting that the anxiolytic-like effects of these compounds are confounded by decreases in locomotor activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740046     DOI: 10.1007/bf02246664

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  Animal models for the study of anti-anxiety agents: a review.

Authors:  D Treit
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

2.  Behavioural effects of novel benzodiazepine (omega) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue.

Authors:  D.J. Sanger
Journal:  Behav Pharmacol       Date:  1995-03       Impact factor: 2.293

3.  Diazepam changes risk assessment in an anxiety/defense test battery.

Authors:  D C Blanchard; R J Blanchard; P Tom; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes.

Authors:  S Z Langer; S Arbilla
Journal:  Pharmacol Biochem Behav       Date:  1988-04       Impact factor: 3.533

5.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

6.  Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor.

Authors:  G Puia; I Ducic; S Vicini; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

Review 7.  Novel anxiolytics that act as partial agonists at benzodiazepine receptors.

Authors:  W Haefely; J R Martin; P Schoch
Journal:  Trends Pharmacol Sci       Date:  1990-11       Impact factor: 14.819

8.  Evidence for central benzodiazepine receptor heterogeneity from behavior tests.

Authors:  M F Davies; E S Onaivi; S W Chen; P A Maguire; N F Tsai; G H Loew
Journal:  Pharmacol Biochem Behav       Date:  1994-09       Impact factor: 3.533

9.  Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol.

Authors:  J C Cole; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

10.  Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.

Authors:  S Pellow; S E File
Journal:  Pharmacol Biochem Behav       Date:  1986-03       Impact factor: 3.533

View more
  21 in total

1.  Effects of zolpidem on sedation, anxiety, and memory in the plus-maze discriminative avoidance task.

Authors:  Karina A Zanin; Camilla L Patti; Leandro Sanday; Luciano Fernandes-Santos; Larissa C Oliveira; Dalva Poyares; Sergio Tufik; Roberto Frussa-Filho
Journal:  Psychopharmacology (Berl)       Date:  2012-06-23       Impact factor: 4.530

2.  Amygdala-specific reduction of alpha1-GABAA receptors disrupts the anticonvulsant, locomotor, and sedative, but not anxiolytic, effects of benzodiazepines in mice.

Authors:  Scott A Heldt; Kerry J Ressler
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

3.  Bidirectional effects of benzodiazepine binding site ligands on active avoidance acquisition and retention: differential antagonism by flumazenil and beta-CCt.

Authors:  Miroslav M Savić; Dragan I Obradović; Nenad D Ugresić; James M Cook; P V V S Sarma; Dubravko R Bokonjić
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

4.  GABAA Receptor Subtypes and the Reinforcing Effects of Benzodiazepines in Remifentanil-Experienced Rhesus Monkeys.

Authors:  Lais F Berro; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2020-05-25       Impact factor: 4.492

Review 5.  The behavioral pharmacology of zolpidem: evidence for the functional significance of α1-containing GABA(A) receptors.

Authors:  Amanda C Fitzgerald; Brittany T Wright; Scott A Heldt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

6.  The involvement of magnoflorine in the sedative and anxiolytic effects of Sinomeni Caulis et Rhizoma in mice.

Authors:  June Bryan I de la Peña; Hye Lim Lee; Seo Young Yoon; Gun Hee Kim; Yong Soo Lee; Jae Hoon Cheong
Journal:  J Nat Med       Date:  2013-03-03       Impact factor: 2.343

7.  Blonanserin - A Novel Antianxiety and Antidepressant Drug? An Experimental Study.

Authors:  Ramchandra Prabhakar Limaye; Aditi Nitin Patil
Journal:  J Clin Diagn Res       Date:  2016-09-01

8.  The α2,3-selective potentiator of GABAA receptors, KRM-II-81, reduces nociceptive-associated behaviors induced by formalin and spinal nerve ligation in rats.

Authors:  J M Witkin; R Cerne; P G Davis; K B Freeman; J M do Carmo; J K Rowlett; K R Methuku; A Okun; S D Gleason; X Li; M J Krambis; M Poe; G Li; J M Schkeryantz; R Jahan; L Yang; W Guo; L K Golani; W H Anderson; J T Catlow; T M Jones; F Porreca; J L Smith; K L Knopp; J M Cook
Journal:  Pharmacol Biochem Behav       Date:  2019-02-27       Impact factor: 3.533

9.  Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase.

Authors:  S F Kash; L H Tecott; C Hodge; S Baekkeskov
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

10.  Acute administration of leptin produces anxiolytic-like effects: a comparison with fluoxetine.

Authors:  Jing Liu; Jacob C Garza; Jamaur Bronner; Chung Sub Kim; Wei Zhang; Xin-Yun Lu
Journal:  Psychopharmacology (Berl)       Date:  2009-10-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.